Market News

Marvel Biosciences Initiates Four Week Rat GLP Toxicology Study

Marvel Biosciences Initiates Four Week Rat GLP Toxicology Study

Marvel Biosciences Corp. (TSXV: MRVL) and its wholly owned subsidiary, Marvel Biotechnology Inc. (collectively the "Company" or "Marvel"), is pleased to announce that it has initiated the 4-week good laboratory practice (GLP) FDA investigational new drug (IND) enabling dose-ranging rat studies for its lead drug candidate MB-204.

"This rat study, along with the GLP study on dogs, are the last two key studies we need to complete before entering phase 1 human clinical testing of our lead asset - MB-204," said Dr. Mark Williams, Chief Science Officer of Marvel Biosciences. "We are also in the final preparation stage of initiating the 4-week dose-ranging GLP studies on dogs and will update our shareholders on our progress shortly."

"We look forward to completing these two critical studies of MB-204 and entering human trials in the coming months, which is an important value-creating milestone for Marvel and our shareholders," said Rod Matheson, CEO of Marvel Biosciences. "MB-204 to date has shown very promising results, and we believe that this asset has the potential to reduce symptoms of depression and Alzheimer's, both of which are significant and growing problems. We look forward to advancing our lead asset MB-204 through human trials and playing a pivotal role in addressing this growing addressable market."

In the United States, it is estimated that one in ten senior citizens over the age of 65 suffer from dementia. MB-204 is a novel solution to Alzheimer's that has similar properties to the Food and Drug Administration-approved drug, Istradefylline. MB-204 has, through the Company's studies, proven to be more effective and longer lasting than Istradefylline in pre-clinical studies.

MB-204 is a fluorinated derivative of the U.S. FDA-approved adenosine A2a receptor antagonist, Istradefylline. Both Istradefylline and MB-204 are highly active derivatives of caffeine, the most widely consumed psychoactive drug in the world. Caffeine consumption has been associated with a reduced risk of developing Parkinson's disease, and Alzheimer's disease and improved concentration.

About Marvel Biosciences Corp.
Marvel Biosciences Corp., and its wholly owned subsidiary, Marvel Biotechnology Inc., is a Calgary-based pre-clinical stage pharmaceutical development biotechnology company that utilizes a "drug redevelopment" approach to drug development. Historically, when a new class of drug is developed, it is optimized for a particular target, but typically only approved for a specific disease. Often, a new disease is identified which involves the same target, however, pending the remaining patent life, the originally approved drug may not have sufficient time left for it to be commercially viable to be developed for the new disease indication. Marvel develops new synthetic chemical derivatives of the original approved drug for the new disease indication. Patent protection is sought, as the new potential asset is developed by the Company. The Company believes the business model results in significantly less risk, cost and time to develop its assets compared to traditional biotechnology companies.

Marvel Biotechnology Inc. has currently developed several new chemical entities, using synthetic chemical derivatives of known, off-patent drugs, that inhibit the A2a adenosine receptor with application to neurological diseases (depression & anxiety, Alzheimer's, ADHD), and the non-neurological conditions of cancer and non-alcoholic steatohepatitis. Marvel is also exploring additional undisclosed targets to expand its asset pipeline.

Contact Information

Investor Relations:
Virtus Advisory Group
Tel: 416-644-5081
Email: info@virtusadvisory.com

Marvel Biosciences Corp.
J. Roderick (Rod) Matheson, Chief Executive Officer or
Dr. Mark Williams, President and Chief Science Officer
Tel: 403 770 2469

To view the source version of this press release, please visit https://www.newsfilecorp.com/release/157765

News Provided by Newsfile via QuoteMedia

MRVL
The Conversation (0)
Keynotes, Educational Panels and 70 Companies to Present at the SNN Network Canada Virtual Event on December 7-9, 2021

Keynotes, Educational Panels and 70 Companies to Present at the SNN Network Canada Virtual Event on December 7-9, 2021

The SNN Network Canada Virtual Event will take place on December 7-9, 2021, where 70 SmallCap, MicroCap and NanoCap public and private companies will be presenting via virtual webcast to a global investor audience

The SNN Network Canada Virtual Event begins on Tuesday, December 7, 2021 with the "MicroCap Investing Workshop" starting at 8:00am EST and featuring well-known financial influencers, investors, fund managers, and key opinion leaders including: Dave Barr, Sharon Wang, Paul Andreola, Becky Popoff, Harold Leishman, Sean MacGillis, and more!

News Provided by ACCESSWIRE via QuoteMedia

Keep reading...Show less

Keynotes, Educational Panels and 70 Companies to Present at the SNN Network Canada Virtual Event on December 7-9, 2021

The SNN Network Canada Virtual Event will take place on December 7-9, 2021, where 70 SmallCap, MicroCap and NanoCap public and private companies will be presenting via virtual webcast to a global investor audience

The SNN Network Canada Virtual Event begins on Tuesday, December 7, 2021 with the "MicroCap Investing Workshop" starting at 8:00am EST and featuring well-known financial influencers, investors, fund managers, and key opinion leaders including: Dave Barr, Sharon Wang, Paul Andreola, Becky Popoff, Harold Leishman, Sean MacGillis, and more!

News Provided by ACCESSWIRE via QuoteMedia

Keep reading...Show less
CSE:NUR

NuRAN Wireless Reports Audited Annual Financial Results

NuRAN Wireless Inc. (“NuRAN Wireless” or the “Company”) (CSE:NUR) (OTC:NRRWF) (FSE:1RN) , a leading supplier of mobile and broadband wireless solutions to connect the next billion, is pleased to announce its audited financial results for the twelve months ended October 31, 2018. All dollar amounts are expressed in Canadian currency.

NuRAN Wireless Inc.-Technology Leadership in the Making

Keep reading...Show less
Juniper Networks Announces Date of First Quarter Preliminary Financial Results Conference Call

Juniper Networks Announces Date of First Quarter Preliminary Financial Results Conference Call

Juniper Networks (NYSE: JNPR), a leader in secure, AI-driven networks, today announced it will release preliminary financial results for the quarter ended March 31, 2023 on Tuesday, April 25, 2023 after the close of the market. The Company's senior management will host a conference call that day at 2:00 pm PT.

Commentary by Ken Miller, chief financial officer, reviewing the Company's first quarter financial results, as well as the second quarter 2023 financial outlook, will be published on the Company's website at http://investor.juniper.net . Analysts and investors are encouraged to review this commentary prior to participating in the conference call.

News Provided by Business Wire via QuoteMedia

Keep reading...Show less
Marvel Commences Final Study Required Prior to Initiating Human Trials

Marvel Commences Final Study Required Prior to Initiating Human Trials

Marvel Biosciences Corp. (TSXV: MRVL) and its wholly owned subsidiary, Marvel Biotechnology Inc. (collectively the "Company" or "Marvel"), is pleased to announce that it has initiated the 4-week good laboratory practice (GLP) FDA investigational new drug (IND) enabling dose-ranging dog studies for its lead drug candidate MB-204.

"This dog study is the last of the two key primary animal studies we need to complete before entering phase 1 human clinical testing of our lead asset - MB-204," said Dr. Mark Williams, Chief Science Officer of Marvel Biosciences. "We are now planning our Phase 1 human trials, likely to be conducted in Australia upon the successful conclusion of this study and the previously commenced 4-week rat GLP study."

News Provided by Newsfile via QuoteMedia

Keep reading...Show less
Enterprise Group Announces Results for Fourth Quarter and Full Year 2022

Enterprise Group Announces Results for Fourth Quarter and Full Year 2022

Enterprise Group, Inc. (TSX: E) (OTCQB: ETOLF) (the "Company" or "Enterprise"). Enterprise, a consolidator of energy services (including specialized equipment rental to the energyresource sector), is pleased to announce its Q4 2022 and FY2022 results.

OVERALL PERFORMANCE AND RESULTS OF OPERATIONS

News Provided by Newsfile via QuoteMedia

Keep reading...Show less
Montfort Capital Reports Strong Preliminary Unaudited Results Within Consumer Lending Segment for FY2022

Montfort Capital Reports Strong Preliminary Unaudited Results Within Consumer Lending Segment for FY2022

Montfort Capital Corp. ("Montfort" or the "Company") (TSXV: MONT) (OTCQB: MONTF) a leading alternative lender utilizing focused strategies, experienced management teams and advanced technology, is pleased to report selected preliminary unaudited results related to its consumer lending segment, which alone has established a significant investment base of over $365 million in Assets Under Management and Administration ("AUMA") as at December 31, 2022 . For comparison, as at December 31, 2021 the Company had $nil AUMA in its consumer lending segment and $125 million in Total Assets. This consumer lending business' growth was driven exponentially through the acquisitions of Brightpath Capital Corporation ("Brightpath") in August 2022 and 78% of Langhaus Financial Partners Inc. ("Langhaus") in October 2022 .

News Provided by Canada Newswire via QuoteMedia

Keep reading...Show less
Montfort Capital Announces Quarterly Cash Dividend on Series A Class A Preferred Shares

Montfort Capital Announces Quarterly Cash Dividend on Series A Class A Preferred Shares

Monfort to pay cash dividend payment to Series A Class A Preferred Shareholders of record on March 24th

Montfort Capital Corp. ("Montfort" or the "Company") (TSXV: MONT) (OTCQB: MONTF), a leading alternative lender utilizing focused strategies, experienced management teams and advanced technology, today announced that the Company's board of directors has declared a quarterly cash dividend (the "Quarterly Dividend") of $0.02 per Series A Class A Preferred Shares (each, a "Preferred Shares"), payable on March 31, 2023 to holders of Preferred Shares of record as  at March 24, 2023 . The Quarterly Dividend qualifies as an 'eligible dividend' for Canadian income tax purposes.

News Provided by Canada Newswire via QuoteMedia

Keep reading...Show less
Marvell Technology, Inc. Declares Quarterly Dividend Payment

Marvell Technology, Inc. Declares Quarterly Dividend Payment

Marvell Technology, Inc. (NASDAQ: MRVL), today announced a quarterly dividend of $0.06 per share of common stock payable on April 26, 2023 to shareholders of record as of April 7, 2023 .

About Marvell

News Provided by PR Newswire via QuoteMedia

Keep reading...Show less

Latest Press Releases

Related News

×